Your browser doesn't support javascript.
Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance
Stephane Le Vu; Gabrielle Jones; Francois Anna; Thierry Rose; Jean-Baptiste Richard; Sibylle Bernard-Stoecklin; Sophie Goyard; Caroline Demeret; Olivier Helynck; Corinne Robin; Virgile Monnet; Louise Perrin de Facci; Marie-Noelle Ungeheuer; Lucie Leon; Yvonnick Guillois; Laurent Filleul; Pierre Charneau; Daniel Levy-Bruhl; Sylvie van der Werf; Harold Noel.
  • Stephane Le Vu; Sante publique France
  • Gabrielle Jones; Sante publique France
  • Francois Anna; Institut Pasteur
  • Thierry Rose; Institut Pasteur
  • Jean-Baptiste Richard; Sante publique France
  • Sibylle Bernard-Stoecklin; Sante publique France
  • Sophie Goyard; Institut Pasteur
  • Caroline Demeret; Institut pasteur
  • Olivier Helynck; Institut Pasteur
  • Corinne Robin; Cerba Healthcare Division
  • Virgile Monnet; Eurofins-Biomnis
  • Louise Perrin de Facci; Institut Pasteur
  • Marie-Noelle Ungeheuer; Institut Pasteur
  • Lucie Leon; Sante publique France
  • Yvonnick Guillois; Sante publique France
  • Laurent Filleul; Sante publique France
  • Pierre Charneau; Institut Pasteur
  • Daniel Levy-Bruhl; Sante publique France
  • Sylvie van der Werf; Institut Pasteur
  • Harold Noel; Sante publique France
Preprint in English | medRxiv | ID: ppmedrxiv-20213116
ABSTRACT
BackgroundAssessment of cumulative incidence of SARS-CoV-2 infections is critical for monitoring the course and the extent of the epidemic. As asymptomatic or mild cases were typically not captured by surveillance data in France, we implemented nationwide serological surveillance. We present estimates for prevalence of anti-SARS-CoV-2 antibodies in the French population and the proportion of infected individuals who developed potentially protective neutralizing antibodies throughout the first epidemic wave. MethodsWe performed serial cross-sectional sampling of residual sera over three periods prior to (9-15 March), during (6-12 April) and following (11-17 May) a nationwide lockdown. Each sample was tested for anti-SARS-CoV-2 IgG antibodies targeting the Nucleoprotein and Spike using two Luciferase-Linked ImmunoSorbent Assays, and for neutralising antibodies using a pseudo-neutralisation assay. We fitted a general linear mixed model of seropositivity in a Bayesian framework to derive prevalence estimates stratified by age, sex and region. FindingsIn total, sera from 11 021 individuals were analysed. Nationwide seroprevalence of SARS-CoV-2 antibodies was estimated at 0.41% [0.05-0.88] mid-March, 4.14% [3.31-4.99] mid-April and 4.93% [4.02-5.89] mid-May. Approximately 70% of seropositive individuals had detectable neutralising antibodies. Seroprevalence was higher in regions where circulation occurred earlier and was more intense. Seroprevalence was lowest in children under 10 years of age (2.72% [1.10-4.87]). InterpretationSeroprevalence estimates confirm that the nationwide lockdown substantially curbed transmission and that the vast majority of the French population remains susceptible to SARS-CoV-2. Low seroprevalence in school age children suggests limited susceptibility and/or transmissibility in this age group. Our results show a clear picture of the progression of the first epidemic wave and provide a framework to inform the ongoing public health response as viral transmission is picking up again in France and globally. FundingSante publique France.
Full text: Available Collection: Preprints Database: medRxiv Type of study: Observational study / Prognostic study / Randomized controlled trials Language: English Year: 2020 Document Type: Preprint

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Collection: Preprints Database: medRxiv Type of study: Observational study / Prognostic study / Randomized controlled trials Language: English Year: 2020 Document Type: Preprint